Search clinical trials for: BRCA defective

Total 545 results

University of Oxford

Completed

A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA) Defective Tumours (6MP)

Breast Cancer | Ovarian Cancer

United Kingdom
858 Therapeutics, Inc.

Recruiting

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies (ERADIC8)

Breast Cancer | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Prostate Cancer | Endometrial Cancer | Epithelial Ovarian Cancer | BRCA1 Mutation | BRCA2 Mutation | Advanced or Metastatic Solid Tumors | ER+ Breast Cancer | Castrate Resistant Prostate Cancer | BRCA Mutation

United States
Radboud University Medical Center

Not yet recruiting

International Registration of Isolated STIC: to Report and Investigate the Risk of Serous Peritoneal Carcinomatosis (STICRISC)

Peritoneal Carcinoma | Ovarian Carcinoma | Serous Tubal Intraepithelial Carcinoma | BRCA Mutation
Qian Qin
Janssen, LP; UT Southwestern Comprehensive Cancer Center

Not yet recruiting

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations (HARMONY)

BRCA1 Gene Mutation | BRCA2 Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | CHEK2 Gene Mutation | FANCA Gene Mutation | RAD51B Gene Mutation | RAD54L Gene Mutation | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Deleterious HRR Gene Mutation
Cairo University

Not yet recruiting

Composite Repair Using Silane Coupling Agent

Hypersensitivity | Tooth Discoloration | Dental Restoration Failure of Marginal Integrity | Tooth Fracture
Acerand Therapeutics (Shanghai) Limited

Recruiting

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

Breast Cancer | Ovarian Cancer | Prostate Cancer | BRCA1 Mutation | BRCA2 Mutation | Solid Tumor, Adult

China
AstraZeneca

Not yet recruiting

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (EvoPAR-BR01)

Advanced Breast Cancer

Canada
Assiut University

Not yet recruiting

BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary

Ovarian Cancer
Comenius University

Recruiting

Stress-Reducing Intervention in Patients With Colorectal and Breast Cancer (SRI-BrCa_CRC)

Breast Cancer | Colon Cancer

Slovakia
Virginia G. Kaklamani

Not yet recruiting

Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)

Triple Negative Breast Cancer | DNA Damage Repair Deficiency

United States
German Breast Group
GlaxoSmithKline; Stemline Therapeutics, Inc.

Not yet recruiting

Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer (ELEMENT)

BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | Hormone Receptor Positive HER-2 Negative Breast Cancer | Advanced or Metastatic Breast Cancer

Germany
Roswell Park Cancer Institute

Not yet recruiting

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors

Malignant Solid Neoplasm | Lung Neuroendocrine Neoplasm | Digestive System Neuroendocrine Neoplasm | Pancreatic Neuroendocrine Neoplasm

United States
Pamela Munster
National Cancer Institute (NCI)

Recruiting

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation | BRCA Mutation | Checkpoint Kinase 2 Gene Mutation

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery

Breast Cancer

United States
Alexander B Olawaiye, MD
AstraZeneca

Recruiting

Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

Ovarian Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v8 | Pancreatic Carcinoma | Pancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma

United States
Centre Georges Francois Leclerc

Not yet recruiting

Use of an Ultra-rapid BRCA1/2 Status Screening Test in Theranostic Indication: Performance and Interest for Patients and Practitioners (TURBO)

Breast Cancer
Tango Therapeutics, Inc.

Recruiting

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Breast Cancer | Ovarian Cancer | Prostate Cancer | Pancreas Cancer | BRCA1 Mutation | BRCA-Mutated Ovarian Carcinoma | BRCA-Associated Breast Carcinoma | HRD Positive Advanced Ovarian Cancer

United States
Sun Yat-sen University

Not yet recruiting

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Ovarian Cancer | Primary Peritoneal Cancer | High Grade Serous Adenocarcinoma of Ovary | High Grade Endometrioid Ovarian Cancer | Fallopian-tube Cancer

China
European Institute of Oncology
Istituto Oncologico Veneto IRCCS; Ente Ospedaliero Ospedali Galliera; Istituto...

Not yet recruiting

Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion (TOLERANT)

Ductal Carcinoma in Situ | RAD51C Gene Mutation | RAD51D Gene Mutation | PALB2 Gene Mutation | Lobular Carcinoma in Situ | ATM Gene Mutation | CDH1 Gene Mutation | CHEK2 Gene Mutation | BRCA Mutation

Italy
OncoNano Medicine, Inc.

Recruiting

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. (ON-5001)

Lymphoma, Non-Hodgkin | Follicular Lymphoma | Carcinoma in Situ | Mantle Cell Lymphoma | Metastatic Cancer | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Cervix Cancer | Diffuse Large B Cell Lymphoma | Head and Neck Squamous Cell Carcinoma | Tumor, Solid | Tumor Recurrence | Uveal Melanoma, Recurrent

United States
National Cancer Institute (NCI)

Recruiting

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

Mesothelioma | BRCA1-Associated Protein-1 (BAP1) Mutations | Malignant Mesothelioma (MM) | Early-stage Mesothelioma | Subclinical Mesothelioma | Early-stage BAP1-associated Malignancies

United States
Ain Shams University

Not yet recruiting

Evaluation of CAD/CAM Onlays Fabricated by Subtractive Versus Additive Digital Manufacturing Techniques.

Caries,Dental | Fracture Tooth | Broken Teeth | Defective Dentition
AstraZeneca

Recruiting

A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA (ERA)

Breast Cancer

Russian Federation
Centre Hospitalier Universitaire de la Réunion

Not yet recruiting

Contribution of Oncogenetics in Breast Cancer in Reunion Epidemiology of Breast Cancer in Reunion: Study of the Reunion Mutation on BRCA2 (CanSeR-OGen)

Breast Cancer | BRCA2 Mutation | Genetic Disease
Regina Elena Cancer Institute

Recruiting

Psyco Quality of Life and Procreation BRCA1/2 (QoL)

Breast Cancer | Genetic Predisposition

Italy
The First Affiliated Hospital with Nanjing Medical...
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer

TNBC - Triple-Negative Breast Cancer

China
Centro di Riferimento Oncologico - Aviano

Recruiting

InheriteD brEast caNcer iTalian regIsTrY A Retrospective-prospective Observational Cohort Study to Evaluate Cancer Prevention Strategies in Women With a Deleterious Mutation in BRCA1-2 (IDENTITY)

Breast Cancer

Italy
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

Prostate Adenocarcinoma | Stage IIIB Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8

United States
IDEAYA Biosciences

Recruiting

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Breast Cancer | Ovarian Cancer | Prostate Cancer | Pancreas Cancer | Advanced or Metastatic Solid Tumors

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

PREDICTION OF GERMLINE BRCA 1/2 GENES FROM HEALTHY OVARIES

Ovarian Cancer | Ultrasound Therapy; Complications | BRCA Mutation

Italy
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation (Gen-eva)

BRCA-Associated Breast Carcinoma

Italy
Ruijin Hospital

Not yet recruiting

Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian Cancer

Ovarian Cancer
University of California, San Francisco
GlaxoSmithKline

Recruiting

Combination Therapy in Cancers With Mutations in DNA Repair Genes

Metastatic Solid Tumor | BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation

United States
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

Lynch Syndrome | Pancreatic Ductal Adenocarcinoma | Chronic Pancreatitis | Pancreatic Cyst | Ataxia Telangiectasia | FAP | Peutz-Jeghers Syndrome | PALB2 Gene Mutation | BRCA Mutation | Fatty Pancreas | Genetic Pancreatic Cancer | Genetic Pancreatitis | Familial Atypical Multiple Mole-Melanoma

United States
Heinrich-Heine University, Duesseldorf
German Cancer Aid

Not yet recruiting

Prostate Cancer Prevention Clinic for Men With Risk of Familial Prostate Cancer (ProFam-Risk)

Prostate Cancer | Familial Prostate Cancer
City of Hope Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma

United States
Northwestern University
Northwestern Memorial Hospital; Saint Joseph Hospital, Chicago, Illinois

Recruiting

Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage

Breast Cancer | BRCA Mutation

United States
Liz-Anne Lewsley
Ovarian Cancer Action

Recruiting

Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma (BriTROC-2)

Ovarian Cancer | Fallopian Tube Cancer | BRCA1 Mutation | BRCA2 Mutation | High Grade Serous Carcinoma | Primary Peritoneal Carcinoma | Carcinosarcoma, Ovarian

United Kingdom
Hebei Medical University Fourth Hospital

Not yet recruiting

Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer

Solid Tumor
Rana McKay, MD
University of California, San Diego; AstraZeneca

Recruiting

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations (NePtune)

Prostate Cancer | BRCA1 Mutation | BRCA2 Mutation | Prostatic Adenocarcinoma | High-Risk Cancer

United States
AstraZeneca

Recruiting

Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer (OlympiaN)

Breast Cancer

United States, Israel, Germany, Italy, Spain, Australia, Austria, Belgium, United Kingdom, France
Okayama University
Merck Sharp & Dohme LLC

Recruiting

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Breast Cancer | Breast Neoplasms | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | BRCA1 Mutation | BRCA2 Mutation | BRCA Mutation | BRCA-Associated Breast Carcinoma

Japan
Yonsei University

Recruiting

Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or Recurrent Ovarian Cancer Patients With Germline Mutation.

Ovarian Cancer

Korea, Republic of
Azienda Socio Sanitaria Territoriale degli Spedali...

Recruiting

Quality of Sexual Function in BRCA Mutated Women (BRCA_SFQ28)

Sexual Dysfunction | Sexual Dysfunctions, Psychological | Sexual Dysfunction, Physiological | BRCA Mutation

Italy
Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations

Breast Cancer Metastatic

China
Memorial Sloan Kettering Cancer Center

Recruiting

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk

BRCA1 Mutation | BRCA2 Mutation | APC Gene Mutation | MLH1 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | PTEN Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | BARD1 Gene Mutation | MSH2 Gene Mutation | MSH6 Gene Mutation | PMS2 Gene Mutation | POLD1 Gene... and other conditions

United States
European Institute of Oncology

Recruiting

LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients (LobularCard)

BRCA1 Mutation | BRCA2 Mutation | Lobular Breast Carcinoma | Lobular in Situ Breast Carcinoma

Italy
Fundació Institut de Recerca de l'Hospital de la...

Recruiting

Study of Quality of Life Post Salpingo-oophorectomy in BRCA1/2 & PALB2 Mutation Carriers (BRCA-HRT) (BRCA-HRT)

Hereditary Breast and Ovarian Cancer

Spain
Banaras Hindu University

Recruiting

of Androgen Receptor Expression in Breast Cancer With or Without BRCA Mutation

Breast Cancer

India

Search clinical trials for: BRCA defective

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations